| A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis (NCT07577804) | Chiesi Farmaceutici S.p.A. | 2026-11-01 |
| A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol (NCT07744386) | Chiesi Farmaceutici S.p.A. | 2026-10-27 |
| A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants (NCT07683793) | Chiesi Farmaceutici S.p.A. | 2026-10-14 |
| A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis (NCT07516951) | Chiesi Farmaceutici S.p.A. | 2026-07-08 |
| BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) (NCT07666490) | Chiesi Farmaceutici S.p.A. | 2026-06-28 |
| Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists (NCT07546981) | Chiesi Farmaceutici S.p.A. | 2026-06-26 |
| Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (NCT07301736) | Chiesi Farmaceutici S.p.A. | 2025-12-17 |
| A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease (NCT06328608) | Chiesi Farmaceutici S.p.A. | 2025-07-29 |
| Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding (NCT06941025) | Chiesi Farmaceutici S.p.A. | 2025-05-23 |
| A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa (NCT06917690) | Chiesi Farmaceutici S.p.A. | 2025-04-18 |
| A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 (NCT06900816) | Chiesi Farmaceutici S.p.A. | 2025-03-28 |
| Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study (NCT06892756) | Chiesi Farmaceutici S.p.A. | 2025-03-18 |
| Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3 (NCT06184503) | Chiesi Farmaceutici S.p.A. | 2025-02-19 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure (NCT06746064) | Chiesi Farmaceutici S.p.A. | 2025-01-13 |
| A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients (NCT06663358) | Chiesi Farmaceutici S.p.A. | 2024-11-06 |
| Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy (NCT06679270) | Chiesi Farmaceutici S.p.A. | 2024-10-14 |
| Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY) (NCT06480890) | Chiesi Farmaceutici S.p.A. | 2024-07-02 |
| Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers (NCT06395610) | Chiesi Farmaceutici S.p.A. | 2024-03-28 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis (NCT06166056) | Chiesi Farmaceutici S.p.A. | 2023-11-29 |
| Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). (NCT06264674) | Chiesi Farmaceutici S.p.A. | 2023-11-27 |
| Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy (NCT06029595) | Chiesi Farmaceutici S.p.A. | 2023-11-26 |
| Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease (NCT05710692) | Chiesi Farmaceutici S.p.A. | 2023-08-01 |
| Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance (NCT05875025) | Chiesi Farmaceutici S.p.A. | 2023-06-26 |
| Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (NCT05898984) | Chiesi Farmaceutici S.p.A. | 2023-04-24 |
| A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) (NCT05830071) | Chiesi Farmaceutici S.p.A. | 2023-03-29 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD). (NCT05513950) | Chiesi Farmaceutici S.p.A. | 2023-01-25 |
| PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI) (NCT05652439) | Chiesi Farmaceutici S.p.A. | 2022-12-02 |
| A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma (NCT05472662) | Chiesi Farmaceutici S.p.A. | 2022-08-03 |
| PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers (NCT05431426) | Chiesi Farmaceutici S.p.A. | 2022-07-29 |
| Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects (NCT05373953) | Chiesi Farmaceutici S.p.A. | 2022-05-05 |
| A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (NCT04320342) | Chiesi Farmaceutici S.p.A. | 2022-04-28 |
| Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality (NCT03992443) | Chiesi Farmaceutici S.p.A. | 2022-02-28 |
| Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA (NCT05018598) | Chiesi Farmaceutici S.p.A. | 2022-02-25 |
| Study in Adult Patients With Moderate to Severe Asthma (NCT04886999) | Chiesi Farmaceutici S.p.A. | 2022-02-24 |
| Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion (NCT05186324) | Chiesi Farmaceutici S.p.A. | 2022-01-26 |
| Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL (NCT05164341) | Chiesi Farmaceutici S.p.A. | 2021-12-17 |
| TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD (NCT04671355) | Chiesi Farmaceutici S.p.A. | 2021-10-04 |
| A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (NCT04636801) | Chiesi Farmaceutici S.p.A. | 2021-07-14 |
| A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (NCT04636814) | Chiesi Farmaceutici S.p.A. | 2021-07-12 |
| A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration (NCT02772081) | Chiesi Farmaceutici S.p.A. | 2021-05-18 |
| Functional Respiratory Imaging Study (DARWiIN) (NCT04876677) | Chiesi Farmaceutici S.p.A. | 2021-05-18 |
| Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects (NCT04756960) | Chiesi Farmaceutici S.p.A. | 2021-03-10 |
| Study on Patterns of Care in Mild Asthmatic Patients (NCT04598555) | Chiesi Farmaceutici S.p.A. | 2021-02-25 |
| Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast) (NCT04739774) | Chiesi Farmaceutici S.p.A. | 2021-02-22 |
| Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis (NCT04031066) | Chiesi Farmaceutici S.p.A. | 2021-01-11 |
| Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS) (NCT04502433) | Chiesi Farmaceutici S.p.A. | 2021-01-06 |
| CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome (NCT04104646) | Chiesi Farmaceutici S.p.A. | 2020-12-18 |
| ARCANGELO (itAlian pRospective Study on CANGrELOr) (NCT04471870) | Chiesi Farmaceutici S.p.A. | 2020-10-23 |
| Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality (NCT03594175) | Chiesi Farmaceutici S.p.A. | 2020-02-12 |
| Registry Study of Revcovi Treatment in Patients With ADA-SCID (NCT03878069) | Chiesi Farmaceutici S.p.A. | 2019-09-30 |
| Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma (NCT04049175) | Chiesi Farmaceutici S.p.A. | 2019-08-28 |
| Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's Adherence (NCT03951714) | Chiesi Farmaceutici S.p.A. | 2019-08-12 |
| Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects (NCT04032535) | Chiesi Farmaceutici S.p.A. | 2019-07-24 |
| A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis (NCT04010799) | Chiesi Farmaceutici S.p.A. | 2019-05-27 |
| PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects (NCT03942666) | Chiesi Farmaceutici S.p.A. | 2019-05-10 |
| Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients (NCT03795350) | Chiesi Farmaceutici S.p.A. | 2019-01-14 |
| Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients (NCT03614234) | Chiesi Farmaceutici S.p.A. | 2018-11-13 |
| Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease (NCT03566017) | Chiesi Farmaceutici S.p.A. | 2018-09-16 |
| The Adherence of Immunosuppressive Therapy Including Tacrolimus Once-daily in Italian Kidney Transplant Recipients (NCT03558373) | Chiesi Farmaceutici S.p.A. | 2018-07-31 |
| Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) (NCT03590379) | Chiesi Farmaceutici S.p.A. | 2018-06-15 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366 (NCT03378648) | Chiesi Farmaceutici S.p.A. | 2017-12-28 |
| Functional Respiratory Imaging Study (FRI) (NCT03268226) | Chiesi Farmaceutici S.p.A. | 2017-11-20 |
| Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma. (NCT03453112) | Chiesi Farmaceutici S.p.A. | 2017-10-09 |
| A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) (NCT03086460) | Chiesi Farmaceutici S.p.A. | 2017-09-08 |